Hand eczema

ASN002 (Gusacitinib) Emerging Drug Insight and Market 2023 - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 23, 2023
Health, Pharmaceutical, Janus, Clinical trial, HE, JAK, JAK3, News, SYK, B cell, JAK1, Research, United Kingdom, EU4, T helper 17 cell, Keratinocyte, CHE, T helper cell, Neutrophil, Book, Pancreatic serous cystadenoma, Macrophage, JAK2, TYK2, Cytokine, Lymphoma, Epithelium, SWOT, Fine chemical, Pharmaceutical industry, Vaccine, Hand eczema

The "ASN002 (Gusacitinib) Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "ASN002 (Gusacitinib) Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
  • Further, it also consists of future market assessments inclusive of the ASN002 (Gusacitinib) market forecast, analysis for Hand Eczema in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Hand Eczema.
  • Other emerging products for Hand Eczema (HE) are expected to give tough market competition to ASN002 (Gusacitinib) and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • What is the clinical trial status of the study related to ASN002 (Gusacitinib) in Hand Eczema (HE) and study completion date?

LEO Pharma Announces Positive Phase 3 Topline Results From DELTA 1 Trial With Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (CHE)

Retrieved on: 
Tuesday, December 6, 2022
Pharmaceutical, Health, Clinical Trials, Janus, Leo Pharma, Immune system, DELTA, Patient, Prevalence, Science, DKK, JAK, CHE, LEO, Research, Hyperkeratosis, Disease, Pain, Fissure, Quality of life, Erythema, Week, Itch, Hand eczema, HE, Skin, Safety, JT, Edema, Dermatology, Pharmaceutical industry, Silviculture

LEO Pharma A/S, a global leader in medical dermatology, today announced positive results of the DELTA 1 trial.

Key Points: 
  • LEO Pharma A/S, a global leader in medical dermatology, today announced positive results of the DELTA 1 trial.
  • DELTA 1 is the first of two pivotal phase 3 clinical trials with delgocitinib cream, an investigational topical pan-Janus kinase (JAK)-inhibitor, for the potential treatment of adults with moderate to severe chronic hand eczema (CHE).
  • In addition to the DELTA 1 trial, delgocitinib cream is also being investigated in the second pivotal trial DELTA 2, which is still ongoing.
  • LEO Pharma is currently developing delgocitinib in a cream formulation for the treatment of moderate to severe chronic hand eczema (CHE) in adults.

Global Hand Eczema Market Report to 2032 - Insights, Epidemiology and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Friday, August 12, 2022
Health, Pharmaceutical, III, Hand eczema, Porter's five forces analysis, Disease, Research, Review, Physiology, II, SWOT, Awareness, PESTLE, Growth–share matrix, HE, Pharmaceutical industry, Epidemiology

The "Hand Eczema (HE) - Market Insights, Epidemiology, and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hand Eczema (HE) - Market Insights, Epidemiology, and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
  • Hand Eczema (HE) market report provides current treatment practices, emerging drugs, and their market share of the individual therapies, current and forecasted Hand Eczema (HE) symptoms market size from 2019 to 2032 segmented by seven major markets.
  • The report also covers current Hand Eczema (HE) symptoms treatment practice/algorithm and unmet medical needs to curate the best opportunities.
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global Hand Eczema (HE) market.

Hand Eczema (HE) Epidemiology Forecast Report 2022-2032: Focus on United States, Germany, Spain, Italy, France, United Kingdom, and Japan - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 27, 2022
Cosmetics, Medical Supplies, Retail, Health, Other Health, General Health, HE, Diagnosis, United Kingdom, Epidemiology, Dermatitis, Hand, Classification, Patient, Risk, Population, Mobile phone, Silk, Renewable energy, Vaccine, Hand eczema

This 'Hand Eczema (HE)- Epidemiology Forecast - 2032' report delivers an in-depth understanding of Hand Eczema (HE) historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Key Points: 
  • This 'Hand Eczema (HE)- Epidemiology Forecast - 2032' report delivers an in-depth understanding of Hand Eczema (HE) historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • The disease epidemiology covered in the report provides historical as well as forecasted Hand Eczema (HE) symptoms epidemiology segmented as the total Prevalent cases of Hand Eczema, gender-specific cases of Hand Eczema, severity-specific cases of Hand Eczema, subgroup-specific cases of Hand Eczema, and age-specific cases of Hand Eczema.
  • The report provides the segmentation of Hand Eczema (HE) epidemiology by the Prevalent Cases of Hand Eczema (HE) in 7MM.
  • The report provides Hand Eczema (HE) epidemiology segmentation by age-specific cases of Hand Eczema (HE) in 7MM.

LEO Pharma initiates the first Phase 3 clinical trial with delgocitinib cream in adult patients with moderate-to-severe chronic hand eczema (CHE)

Retrieved on: 
Tuesday, May 18, 2021
Pharmaceutical, Health, Clinical trials, Eczema, Hand eczema, Dermatitis, Dermatology, Janus kinase inhibitor, Clinical medicine, Delgocitinib, LEO Pharma, DELGOCITINIB, LEO PHARMA

LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 93 million patients in 130 countries.

Key Points: 
  • LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 93 million patients in 130 countries.
  • The topical pan-JAK inhibitor delgocitinib cream demonstrates dose response in a 16-week phase 2b trial in chronic hand eczema.
  • A phase 2b trial evaluating the efficacy of delgocitinib cream for the treatment of chronic hand eczema (CHE) using and validating the Hand Eczema Severity Index (HECSI).
  • E-poster presented at the American Academy of Dermatology Virtual Meeting Experience (AAD VMX) 23-25 April 2021.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210517005624/en/\n'

Global Eczema Epidemiology and Patient Flow Report 2021: Market Sizing, Market Potential, and Developing Drug Forecast Models 2020-2035 - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 6, 2021
Health, General Health, Dermatitis, Epidemiology, Hand eczema

b'The "Global Eczema Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Eczema Epidemiology and Patient Flow Analysis - 2021, provides Eczema epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Eczema Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Eczema Epidemiology and Patient Flow Analysis - 2021, provides Eczema epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Eczema patients, history of the disease at the population level (Eczema prevalence, Eczema incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Eczema patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Eczema market sizing, assessing market potential, and developing drug forecast models\nIdentify Eczema patients segments through age groups, gender, and disease sub-types\n'

Arcutis Announces First Quarter 2021 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, May 4, 2021
Eczema, Hand eczema, Dermatitis, ARQ

The robust Phase 3 data also reinforce our optimism for the multiple additional on-going development efforts with topical roflumilast cream and foam.

Key Points: 
  • The robust Phase 3 data also reinforce our optimism for the multiple additional on-going development efforts with topical roflumilast cream and foam.
  • Watanabe continued: \xe2\x80\x9cWe are disappointed with the recent results of the ARQ-252 Phase 1/2b study in chronic hand eczema, a difficult disease to treat, and are undertaking further analyses to understand the data.
  • Arcutis\xe2\x80\x99 robust pipeline includes four novel drug candidates currently in development for a range of inflammatory dermatological conditions.
  • We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.\n'

Arcutis Announces First Patient Enrolled in Phase 2a Clinical Trial Evaluating ARQ-252 as a Potential Treatment for Vitiligo

Retrieved on: 
Thursday, March 18, 2021
Vitiligo, Dermatology, Hand eczema, Organ systems, Medical specialties, Clinical medicine

(Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced enrollment of the first patient in a Phase 2a clinical trial evaluating ARQ-252 as a potential treatment for vitiligo .

Key Points: 
  • (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced enrollment of the first patient in a Phase 2a clinical trial evaluating ARQ-252 as a potential treatment for vitiligo .
  • Approximately 1.3 million people in the U.S. suffer from vitiligo, and there is currently no FDA-approved treatment.
  • Arcutis is also developing ARQ-252 0.3% cream as a potential treatment for chronic hand eczema and expects to report topline data from a Phase 1/2b study in mid-2021.
  • This press release contains "forward-looking" statements, including, among others, statements regarding ARQ-252s potential as a treatment for vitiligo; and expectations with regard to the timing of the Phase 2 clinical trial.

Evelo Biosciences Reports New Positive Confirmatory Data from Phase 1b Trial of EDP1815 in Atopic Dermatitis

Retrieved on: 
Wednesday, January 20, 2021
Steroids, Autoimmune diseases, Medical specialties, Psoriasis, Immunology, Atopic dermatitis, Type I hypersensitivity, Dermatitis, Anti-inflammatory, Pregnanes, Hand eczema

The data shared today reinforce and extend the previously released results, demonstrating that EDP1815 treatment was well tolerated and resulted in clinically meaningful improvements in measures of atopic dermatitis, said Douglas Maslin, M.Phil, M.B.

Key Points: 
  • The data shared today reinforce and extend the previously released results, demonstrating that EDP1815 treatment was well tolerated and resulted in clinically meaningful improvements in measures of atopic dermatitis, said Douglas Maslin, M.Phil, M.B.
  • Together with the previous results in psoriasis, EDP1815 continues to demonstrate the potential to be a safe, effective, well tolerated, oral, broad-spectrum anti-inflammatory therapy.
  • Preclinical and clinical data to date showed that EDP1815 achieved this anti-inflammatory activity without inducing immunosuppression.
  • Beyond topicals, patients have limited treatment options, especially patients with mild and moderate disease, who represent 80-90% of atopic dermatitis patients worldwide.

LEO Pharma announces positive results of Phase 2b dose-finding study with delgocitinib cream in adult patients with mild-to-severe chronic hand eczema (CHE)

Retrieved on: 
Thursday, October 29, 2020
Managed care, Pharmaceutical, Health, Clinical trials, Janus kinase inhibitor, Hand eczema, Corticosteroids, Monoclonal antibodies, Delgocitinib, LEO Pharma

The results of this trial showed that delgocitinib cream may have the potential to become a new treatment option for adult patients suffering from mild-to-severe CHE.

Key Points: 
  • The results of this trial showed that delgocitinib cream may have the potential to become a new treatment option for adult patients suffering from mild-to-severe CHE.
  • Earlier this year, delgocitinib cream received Fast Track designation for the treatment of moderate-to-severe CHE from the U.S. Food and Drug Administration.
  • LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 92 million patients in 130 countries.
  • The topical pan-JAK inhibitor delgocitinib cream demonstrates dose response in a 16-week phase 2b trial in chronic hand eczema.